The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Verona Pharma Plc ADR shares valued at $3,753,000 were purchased by DAVID ZACCARDELLI on May 27 ’25. At $75.06 per share, DAVID ZACCARDELLI acquired 50,000 shares.
Also, MARK HAHN purchased 50,000 shares, netting a total of over 3,753,000 in proceeds.
Before that, Sinha Vikas had sold 160,000 shares from its account. In a trade valued at $1,502,928, the Director traded Verona Pharma Plc ADR shares for $9.39 each. Upon closing the transaction, the insider’s holdings decreased to 160,000 shares, worth approximately $5.5 million.
As published in their initiating research note from TD Cowen on April 28, 2025, Verona Pharma Plc ADR [VRNA] has been a Buy and the price target has been revised to $100. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of January 10, 2025, ROTH MKM has initiated its “Buy” rating for VRNA. Earlier on October 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for VRNA stock.
Analyzing VRNA Stock Performance
During the last five days, there has been a drop of approximately -1.07%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 59.19%. Shares of the company reached a 52-week high of $76.92 on 05/27/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 73.03, which, if violated, would cause prices to drop to 72.12. In the upper region, resistance lies at 75.24. The next price resistance is at 76.54. RSI (Relative Strength Index) is 60.35 on the 14-day chart, showing neutral technical sentiment.
